Targeting bone physiology for the treatment of metastatic prostate cancer Journal Article

Authors: Autio, K. A.; Morris, M. J.
Article Title: Targeting bone physiology for the treatment of metastatic prostate cancer
Abstract: Metastatic prostate cancer has a unique predilection for bone that can lead to significant clinical sequelae, such as fracture and cord compression. This tropism for bone yields not only clinical challenges, but also opportunities to understand the tumor biology in bone and to develop relevant therapeutic strategies. The process by which tumor cells migrate to bone, remain dormant, and then colonize and expand is based on complex interactions between prostate cancer tumor cells and the host microenvironment. This review will provide an overview of these interactions as well as therapies targeting osseous metastases in castration-resistant prostate cancer.
Keywords: platelet derived growth factor; somatomedin; protein expression; bone neoplasms; osteolysis; doxorubicin; cancer growth; unspecified side effect; antineoplastic agents; bone metastasis; pathophysiology; radiopharmaceuticals; cell proliferation; breast cancer; bone morphogenetic protein; transforming growth factor beta; thrombocytopenia; incidence; prevalence; risk factor; vinblastine; physiology; cell transformation, neoplastic; docetaxel; prostate cancer; prostatic neoplasms; alkaline phosphatase; cytokine; clinical trials, phase iii as topic; matrix metalloproteinase; tumor cell; cell migration; single drug dose; ossification; osteoclast; bone and bones; osteoclasts; ketoconazole; toxicity; androgen deprivation therapy; cadherin; bone remodeling; cell expansion; bone scintiscanning; zoledronic acid; osteoblast; bone disease; hypocalcemia; bone resorption; stromal cell derived factor 1; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); chemokine receptor cxcr4; denosumab; jaw osteonecrosis; systematic review (topic); samarium 153; strontium 89; estramustine; cabozantinib; receptor activator of nuclear factor kappa b; phase 4 clinical trial (topic); rankl; radiopharmaceutical; radium-223; radium chloride ra 223
Journal Title: Clinical Advances in Hematology & Oncology
Volume: 11
Issue: 3
ISSN: 1543-0790
Publisher: Millennium Medical Publishing, Inc  
Date Published: 2013-03-01
Start Page: 134
End Page: 143
Language: English
PROVIDER: scopus
PUBMED: 23598981
PMCID: PMC3938391
Notes: --- - "Export Date: 1 July 2013" - "Source: Scopus"